%PDF-1.4
%
1 0 obj
<>
endobj
188 0 obj
<>stream
Creo Normalizer JTP
2024-03-18T21:01:43-07:00
2006-05-16T10:23:21-04:00
2024-03-18T21:01:43-07:00
uuid:f5c94ca8-b020-4df7-9f55-9289ae21abd7
uuid:3aba4ad0-1dd2-11b2-0a00-810088c9a1ff
application/pdf
endstream
endobj
2 0 obj
<>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/Rotate 0/TrimBox[0.0 0.0 585.0 783.0]/Type/Page>>
endobj
59 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/TrimBox[0.0 0.0 585.0 783.0]/Type/Page>>
endobj
105 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/TrimBox[0.0 0.0 585.0 783.0]/Type/Page>>
endobj
139 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/TrimBox[0.0 0.0 585.0 783.0]/Type/Page>>
endobj
205 0 obj
[210 0 R]
endobj
183 0 obj
<>
endobj
206 0 obj
<>stream
BT
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
9 0 0 9 62.1648 754.8835 Tm
[(Advantages)-332.7 (for)-332.7 (Transdermal)-332.7 (over)-332.7 (Oral)-332.7 (Oxybutynin)-332.7 (to)-332.7 (Treat)]TJ
0 -1.1111 TD
[(Overactive)-332.7 (Bladder:)-332.7 (Muscarinic)-332.7 (Receptor)-332.7 (Binding,)-332.7 (Plasma)]TJ
T*
[(Drug)-332.7 (Concentration,)-332.7 (and)-332.7 (Salivary)-332.7 (Secretion)]TJ
/T1_1 1 Tf
29.3333 2.2222 Td
[(Tomomi)-332.7 (Oki,)-332.7 (Ayako)-332.7 (Toma-Okura,)-332.7 (and)]TJ
T*
[(Shizuo)-332.7 (Yamada)]TJ
22 1.1111 Td
(1137)Tj
/T1_0 1 Tf
-51.3333 -3.7778 Td
[(Brain)-332.7 (Cholesterol)-332.7 (Synthesis)-332.7 (in)-332.7 (Mice)-332.7 (Is)-332.7 (Affected)-332.7 (by)-332.7 (High)-332.7 (Dose)]TJ
T*
[(of)-332.7 (Simvastatin)-332.7 (but)-332.7 (Not)-332.7 (of)-332.7 (Pravastatin)]TJ
/T1_1 1 Tf
29.3333 1.1111 Td
[(Karin)-332.7 (M.)-332.7 (Thelen,)-332.7 (Katharina)-332.7 (M.)-332.7 (Rentsch,)]TJ
T*
[(Ursula)-332.7 (Gutteck,)-332.7 (Maura)-332.7 (Heverin,)-332.7 (Maria)-332.7 (Olin,)]TJ
T*
[(Ulla)-332.7 (Andersson,)-332.7 (Arnold)-332.7 (von)-332.7 (Eckardstein,)]TJ
T*
[(Ingemar)-332.7 (Bjo)416.5 (\250)-83.6 (rkhem,)-332.7 (and)-332.7 (Dieter)-332.7 (Lu)416.6 (\250)-83.6 (tjohann)]TJ
22.0001 3.3333 Td
(1146)Tj
/T1_0 1 Tf
-51.3333 -4.8889 Td
[(An)-332.7 (Inverse)-332.7 (Agonist)-332.7 (Selective)-332.7 (for)]TJ
/T1_2 1 Tf
9 0 1.3977 9 191.6117 676.8835 Tm
(\001)Tj
/T1_0 1 Tf
9 0 0 9 197.6144 676.8835 Tm
[(5)-332.7 (Subunit-Containing)]TJ
-15.05 -1.1111 Td
(GABA)Tj
7 0 0 5.5 88.1647 664.8835 Tm
(A)Tj
9 0 0 9 96.2131 666.8835 Tm
[(Receptors)-332.7 (Enhances)-332.7 (Cognition)]TJ
/T1_1 1 Tf
25.5502 1.1111 Td
[(G.)-332.7 (R.)-332.7 (Dawson,)-332.7 (K.)-332.7 (A.)-332.7 (Maubach,)]TJ
T*
[(N.)-332.7 (Collinson,)-332.7 (M.)-332.7 (Cobain,)-332.7 (B.)-332.7 (J.)-332.7 (Everitt,)]TJ
T*
[(A.)-332.7 (M.)-332.7 (MacLeod,)-332.7 (H.)-332.7 (I.)-332.7 (Choudhury,)]TJ
T*
[(L.)-332.7 (M.)-332.7 (McDonald,)-332.7 (G.)-332.7 (Pillai,)-332.7 (W.)-332.7 (Rycroft,)]TJ
T*
[(A.)-332.7 (J.)-332.7 (Smith,)-332.7 (F.)-332.7 (Sternfeld,)-332.7 (F.)-332.7 (D.)-332.7 (Tattersall,)]TJ
T*
[(K.)-332.7 (A.)-332.7 (Wafford,)-332.7 (D.)-332.7 (S.)-332.7 (Reynolds,)]TJ
T*
[(G.)-332.7 (R.)-332.7 (Seabrook,)-332.7 (and)-332.7 (J.)-332.7 (R.)-332.7 (Atack)]TJ
22 6.6667 Td
(1335)Tj
/T1_0 1 Tf
-51.3333 -8.2222 Td
[(Pharmacological)-332.7 (Characterization)-332.7 (of)-332.7 (Agonists)-332.7 (at)]TJ
/T1_2 1 Tf
9 0 1.3977 9 255.1041 602.8835 Tm
(\006)Tj
/T1_0 1 Tf
9 0 0 9 260.1079 602.8835 Tm
(-Containing)Tj
-21.9937 -1.1111 Td
(GABA)Tj
7 0 0 5.5 88.1647 590.8835 Tm
(A)Tj
9 0 0 9 96.2131 592.8835 Tm
[(Receptors:)-332.7 (Functional)-332.7 (Selectivity)-332.7 (for)-332.7 (Extrasynaptic)]TJ
-3.7832 -1.1111 Td
[(Receptors)-332.7 (Is)-332.7 (Dependent)-332.7 (on)-332.7 (the)-332.7 (Absence)-332.7 (of)]TJ
/T1_2 1 Tf
9 0 1.3977 9 231.097 582.8835 Tm
(\003)Tj
/T1_0 1 Tf
7 0 0 5.5 236.5957 580.8835 Tm
(2)Tj
/T1_1 1 Tf
9 0 0 9 326.1648 602.8835 Tm
[(Signe)-332.7 (\031)305.3 (\264)-305.2 (Sto)416.4 (\264)-83.6 (rustovu)-332.7 (and)-332.7 (Bjarke)-332.7 (Ebert)]TJ
22.0003 0 Td
(1351)Tj
/T1_0 1 Tf
-51.3336 -3.7778 Td
(The)Tj
/T1_2 1 Tf
9 0 1.3977 9 80.1615 568.8835 Tm
(\006)Tj
/T1_0 1 Tf
9 0 0 9 88.1596 568.8835 Tm
[(Subunit)-332.7 (of)]TJ
/T1_2 1 Tf
9 0 1.3977 9 132.1627 568.8835 Tm
(\003)Tj
/T1_0 1 Tf
9 0 0 9 137.6615 568.8835 Tm
[(-Aminobutyric)-332.7 (Acid)-332.7 (Type)-332.7 (A)-332.7 (Receptors)]TJ
-8.3885 -1.1111 Td
[(Does)-332.7 (Not)-332.7 (Confer)-332.7 (Sensitivity)-332.7 (to)-332.7 (Low)-332.7 (Concentrations)-332.7 (of)-332.7 (Ethanol)]TJ
/T1_1 1 Tf
29.3333 1.1111 Td
[(Cecilia)-332.7 (M.)-332.7 (Borghese,)-332.7 (Signe)-332.7 (\031)305.7 (\264)-305.2 (Sto)416.4 (\264)-83.6 (rustovu,)]TJ
-0.0001 -1.1111 Td
[(Bjarke)-332.7 (Ebert,)-332.7 (Murray)-332.7 (B.)-332.7 (Herd,)-332.7 (Delia)-332.7 (Belelli,)]TJ
T*
[(Jeremy)-332.7 (J.)-332.7 (Lambert,)-332.7 (George)-332.7 (Marshall,)]TJ
T*
[(Keith)-332.7 (A.)-332.7 (Wafford,)-332.7 (and)-332.7 (R.)-332.7 (Adron)-332.7 (Harris)]TJ
22 3.3333 Td
(1360)Tj
/T1_0 1 Tf
-53.3333 -5.5556 Td
(TOXICOLOGY)Tj
/T1_3 1 Tf
7 0 0 7 49.1648 506.8835 Tm
(\001)Tj
/T1_4 1 Tf
5 0 0 5 51.0569 506.8835 Tm
(S)Tj
/T1_0 1 Tf
9 0 0 9 62.1675 506.8835 Tm
[(Microarray)-332.7 (Analysis)-332.7 (of)-332.7 (Lipopolysaccharide)-332.7 (Potentiation)-332.7 (of)]TJ
-0.0003 -1.2222 Td
[(Trovafloxacin-Induced)-332.7 (Liver)-332.7 (Injury)-332.7 (in)-332.7 (Rats)-332.7 (Suggests)-332.7 (a)-332.7 (Role)]TJ
0 -1.2222 TD
[(for)-332.7 (Proinflammatory)-332.7 (Chemokines)-332.7 (and)-332.7 (Neutrophils)]TJ
/T1_1 1 Tf
29.3333 2.4444 Td
[(Jeffrey)-332.7 (F.)-332.7 (Waring,)-332.7 (Michael)-332.7 (J.)-332.7 (Liguori,)]TJ
0 -1.1111 TD
[(James)-332.7 (P.)-332.7 (Luyendyk,)-332.7 (Jane)-332.7 (F.)-332.7 (Maddox,)]TJ
T*
[(Patricia)-332.7 (E.)-332.7 (Ganey,)-332.7 (Robert)-332.7 (F.)-332.7 (Stachlewitz,)]TJ
T*
[(Colin)-332.7 (North,)-332.7 (Eric)-332.7 (A.)-332.7 (G.)-332.7 (Blomme,)-332.7 (and)]TJ
T*
[(Robert)-332.7 (A.)-332.7 (Roth)]TJ
22 4.4444 Td
(1080)Tj
/T1_0 1 Tf
-51.3333 -6 Td
[(Modulation)-332.7 (of)-332.7 (Expression)-332.7 (of)-332.7 (Rat)-332.7 (Mitochondrial)-332.7 (2-)]TJ
T*
[(Oxoglutarate)-332.7 (Carrier)-332.7 (in)-332.7 (NRK-52E)-332.7 (Cells)-332.7 (Alters)-332.7 (Mitochondrial)]TJ
T*
[(Transport)-332.7 (and)-332.7 (Accumulation)-332.7 (of)-332.7 (Glutathione)-332.7 (and)-332.7 (Susceptibility)]TJ
T*
[(to)-332.7 (Chemically)-332.7 (Induced)-332.7 (Apoptosis)]TJ
/T1_1 1 Tf
29.3333 3.3333 Td
[(Feng)-332.7 (Xu,)-332.7 (David)-332.7 (A.)-332.7 (Putt,)-332.7 (Larry)-332.7 (H.)-332.7 (Matherly,)]TJ
T*
[(and)-332.7 (Lawrence)-332.7 (H.)-332.7 (Lash)]TJ
22 1.1111 Td
(1175)Tj
/T1_0 1 Tf
-51.3333 -4.8889 Td
[(Relationship)-332.7 (between)-332.7 (Temperature,)-332.7 (Dopaminergic)]TJ
T*
[(Neurotoxicity,)-332.7 (and)-332.7 (Plasma)-332.7 (Drug)-332.7 (Concentrations)-332.7 (in)]TJ
T*
[(Methamphetamine-Treated)-332.7 (Squirrel)-332.7 (Monkeys)]TJ
/T1_1 1 Tf
29.3333 2.2222 Td
[(Jie)-332.7 (Yuan,)-332.7 (George)-332.7 (Hatzidimitriou,)]TJ
T*
[(Pranav)-332.7 (Suthar,)-332.7 (Melanie)-332.7 (Mueller,)]TJ
T*
[(Una)-332.7 (McCann,)-332.7 (and)-332.7 (George)-332.7 (Ricaurte)]TJ
22 2.2222 Td
(1210)Tj
/T1_0 1 Tf
-53.3333 -4.4445 Td
[(LETTERS)-332.7 (TO)-332.7 (THE)-332.7 (EDITOR)]TJ
2 -1.3333 Td
[(Comments)-332.7 (on)-332.7 (\223Multiple)-332.7 (Transporters)-332.7 (Affect)-332.7 (the)-332.7 (Disposition)]TJ
T*
[(of)-332.7 (Atorvastatin)-332.7 (and)-332.7 (Its)-332.7 (Two)-332.7 (Active)-332.7 (Hydroxy)-332.7 (Metabolites:)]TJ
T*
[(Application)-332.7 (of)-332.7 (in)-332.7 (Vitro)-332.7 (and)-332.7 (ex)-332.7 (Situ)-332.7 (Systems\224)]TJ
/T1_1 1 Tf
29.3333 2.2222 Td
[(Kari)-332.7 (T.)-332.7 (Kivisto)416.6 (\250)]TJ
22 0 Td
(1386)Tj
/T1_0 1 Tf
-51.3334 -3.7778 Td
[(Response)-332.7 (to)-332.7 (Comments)-332.7 (on)-332.7 (\223Multiple)-332.7 (Transporters)-332.7 (Affect)-332.7 (the)]TJ
T*
[(Disposition)-332.7 (of)-332.7 (Atorvastatin)-332.7 (and)-332.7 (Its)-332.7 (Two)-332.7 (Active)-332.7 (Hydroxy)]TJ
T*
[(Metabolites:)-332.7 (Application)-332.7 (of)-332.7 (in)-332.7 (Vitro)-332.7 (and)-332.7 (ex)-332.7 (Situ)-332.7 (Systems\224)]TJ
/T1_1 1 Tf
29.3333 2.2222 Td
[(Yvonne)-332.7 (Y.)-332.7 (Lau,)-332.7 (Hideaki)-332.7 (Okochi,)]TJ
T*
[(Yong)-332.7 (Huang,)-332.7 (and)-332.7 (Leslie)-332.7 (Z.)-332.7 (Benet)]TJ
22 1.1111 Td
(1387)Tj
/T1_3 1 Tf
11 0 0 11 35.1648 90.8835 Tm
(\001)Tj
/T1_4 1 Tf
9 0 0 9 38.1355 90.8835 Tm
(S)Tj
10 0 0 10 48.8053 90.8835 Tm
[(Supplemental)-332.9 (material)-332.9 (is)-332.9 (available)-332.9 (online)-332.9 (at)-332.9 (http://jpet.aspetjournals.org.)]TJ
/T1_5 1 Tf
0.136 -4.3 Td
[(About)-232.1 (the)-232.1 (cover:)]TJ
/T1_4 1 Tf
7.7228 0 Td
[(Histopathological)-232.1 (damages)-232.1 (in)-232.1 (liver)-232.1 (in)-232.1 (rats)-232.1 (given)-232.1 (LPS)-232.1 (and)-232.1 (cotreated)-232.1 (with)-232.1 (TVX)-232.1 (or)-232.1 (LVX.)-232.1 (See)]TJ
-7.7228 -1.2 Td
[(the)-332.9 (article)-332.9 (by)-332.9 (Waring)-332.9 (et)-332.9 (al.)-332.9 (on)-332.9 (page)-332.9 (1080)-332.9 (of)-332.9 (this)-332.9 (issue.)]TJ
ET
1 0 0 1 -9 -9 cm
/CS0 CS 1 SCN
52 w
/GS1 gs
44.165 52.884 m
47.165 52.884 l
S
3 w
47.165 77.383 m
560.165 77.383 l
S
52 w
557.165 52.884 m
560.165 52.884 l
S
3 w
44.165 28.384 m
557.165 28.384 l
S
1 0 0 1 9 9 cm
BT
0 g
/GS2 gs
/T1_6 1 Tf
0 -9 9 0 568 389.50653 Tm
( at ASPET Journals on March 18, 2024)Tj
/GS2 gs
-8.61 0 Td
(jpet.aspetjournals.org)Tj
/GS2 gs
-7.55399 0 Td
(Downloaded from )Tj
ET
endstream
endobj
168 0 obj
<>
endobj
142 0 obj
<>
endobj
145 0 obj
<>
endobj
149 0 obj
<>
endobj
153 0 obj
<>
endobj
158 0 obj
<>
endobj
161 0 obj
<>
endobj
195 0 obj
<>
endobj
162 0 obj
<>
endobj
163 0 obj
<>stream
HTiPga{ 9Ff7D11&"ȊN8pHBpDP@ fP:`ϕH@vDcpTtI%?Uyy>&D"2h3hb5iY!qQ;}Wk"-.xFOv="T<&B`KpWF$ښNJ(g(/\0rYO?WRG(B51IuZ&F5[LLTldHWlII&¤Fb316
|D/ƖbJ)6Kh`"hMMxYCrmH%lcIv;(u\XFEvusŘH
lWPitm)Å:Q}|}p6%%IGu
&w)Ylx"JʓS!Eh9[כtd0]pKlRU[0Q i,{3 lFtg9qF2>Y]2!ߍE˵##geIPA+|P8"2priy@+HSu7ԙ
4{8ǂ35Fmx{X|SV˩"٨`K/E+zT$`:$ARf:S Uph@8^T%i˕ű@\eMĢ9E2[(2)U؊} SOk1{D?C=UkH`Ifw$7eK'
DNH!L-{vTDeb
g 8蒚
Hhx}kYɑ,٭L>6IA_ n fP
B(C0c.ZS91mp`z=BRHCGzL؋O D@,XېzE ip
rDv%캕lߩo?ncClCu_0^᠍`+{@,P璍bf#2Vw(ѕ"HSa£PO&hiXEDU#nV>C
8`BQW(}h~[ol Aq[DٜĚ>ѐ%h4>/c}Gll